HOME >> BIOLOGY >> NEWS
Early promise for treatment of Ebola

Preliminary findings of an animal study in this week's issue of THE LANCET suggest that scientists have taken an important step towards a possible treatment strategy for the deadly Ebola virus.

Haemorragic fever from the Ebola virus is fatal in up to 80%of cases in humans. The virus is thought to cause excessive blood coagulation and thrombosis leading to organ dysfunction. Inhibition of the blood coagulation pathway could therefore be a potential therapeutic approach for ebola treatment.

Thomas W Geisbert from the US Army Medical Research Institute of Infectious Diseases and colleagues injected 12 rhesus macaques with the ebola virus to induce the deadly ebola haemorragic fever. Nine of the macaques received an inhibitor of the blood coagulation pathway (called recombinant nematode anticoagulant protein c2, rNAPc2), while three macaques received the ebola virus only (the control group).

Treatment with rNAPc2 prolonged survival time and resulted in a 33% survival rate; this contrasted with macaques in the control group, of whom all except one died (since the study was completed the remaining control animal has also died). The surviving macaques in the treatment group were in good health nine months after the study. Survival was longer (12 days) for treated macaques who died compared with untreated macaques in the control group (8 days).

Thomas W Geisbert comments: "Our results have great clinical implications, since our treatment approach of Ebola haemorrhagic fever targets the disease process rather than replication of the infectious agent. Moreover, our findings raise the possibility that rNAPc2 could be useful in the treatment of other viral haemorrhagic fevers. Importantly, rNAPc2 has a suitable phamacokinetic and safety profile in human beings. The clinical efficacy of this treatment modality now needs to be proven."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
11-Dec-2003


Page: 1

Related biology news :

1. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
2. Early detection hope for eye disease
3. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
4. Early dexamethasone exposure has long-term neurodevelopment, neuroendocrine effects
5. Early predictor of breast cancer aggressiveness
6. Early treatment confirmed as key to stroke recovery
7. Early identification of kidney disease cost-effective only when directed at high-risk patients
8. Early treatment can prevent severe vision loss in premature infants
9. Early hominids may have behaved more human than we had thought
10. Early infection and rejection detection
11. Early-life environments shape development of stress behaviors and learning abilities in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , a ... for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology Association ... of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 single ...
(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode scheduled for ... Point of Care Testing solutions (POCT). Check local listings for more info. , Today, ... offices and are shipped to labs throughout the country. Results are then available several ...
(Date:6/23/2020)... ... 23, 2020 , ... Rigaku Corporation , a global ... a series of TOPIQ webinars, which will cover the Transferable Aspherical Atom Model ... response to social distancing measures that resulted in postponements and cancelations of global ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... ... is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency ... led by Dr MA has been using the zebrafish model to investigate the ...
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World ... Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, ... an elite awards program, highlighting outstanding examples of how technology innovations and strategic ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight ... microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, ...
(Date:6/28/2020)... Conn. (PRWEB) , ... June 25, 2020 , ... ... formed to advance photodynamic therapy for treating cancer, today announced the company has ... York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell ...
Breaking Biology Technology:
Cached News: